Zorana Budakov Obradovic

Zorana Budakov Obradovic

Auto-generated profile, based on publicly available information

Zorana Budakov Obradovic

Blood Transfusion Institute Vojvodina, 21000 Novi Sad, Serbia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Transfusion Medicine
Verified
Journal Article
Closed access
MBMilomir Radoslav Bezanovic
Milomir Radoslav Bezanovic
ZOZorana Budakov Obradovic
Zorana Budakov Obradovic
NBNevenka Bujandric
Nevenka Bujandric
NKNeda Kocić
Neda Kocić
MMMirjana Krga Milanovic
Mirjana Krga Milanovic
JGJasmina Grujic
Jasmina Grujic

6 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
TRTomás Cervantes Rincón
Tomás Cervantes Rincón
TFTereza Frckova
Tereza Frckova
ZCZaria I. Contejean
Zaria I. Contejean
JOJasmine Oberti-Cantergiani
Jasmine Oberti-Cantergiani
KGKevin Groen
Kevin Groen
DRDavide F. Robbiani
Davide F. Robbiani
West Nile virus (WNV) is a mosquito-borne pathogen of global concern that can cause fatal neuroinvasive disease. No specific prophylaxis or treatment exists for WNV or related orthoflavivirus infections, and the determinants of human disease severity remain poorly understood. Here, we report that neutralizing autoantibodies against type I interferons do not impair antiviral antibody development. Among the fully human monoclonal antibodies with potent neutralizing activity against WNV that were discovered, W010 targets a unique epitope within the envelope protein domain III (EDIII) and confers both pre- and post-exposure protection in a murine WNV model, even when interferon signaling is impaired. A second protective antibody, W014, exhibits broad cross-neutralization of other pathogenic orthoflavivirus members, including Japanese encephalitis virus, Murray Valley encephalitis virus, Saint Louis encephalitis virus, and Usutu virus. These findings identify key neutralizing epitopes on WNV EDIII and provide candidates for the development of antibody-based interventions against encephalitic orthoflavivirus infections.